Introduction {#s1}
============

The transport of drugs in and out of tissues and cells is now recognized as an important factor in drug efficacy and toxicity (International Transporter et al., [@B22]; Hillgren et al., [@B19]). Drug transport occurs at key sites including the liver, kidney, intestine, and blood-brain barrier to regulate drug and/or metabolite distribution (International Transporter et al., [@B22]; Hillgren et al., [@B19]). Understanding the regulation of drug transporter gene expression is important to improve drug efficacy and toxicity, especially for the many drugs transported into and out of the liver. Drug transport into and out of the liver is controlled by two superfamilies of transporters, the solute carrier transporters (SLC) and the ATP Binding Cassette transporters (ABC). Among these transporters, 32 have currently been designated as clinically relevant drug transporters (pharmADME.org; International Transporter Consortium; International Transporter et al., [@B22]; Hillgren et al., [@B19]). For most of these transporters, gene expression has not been studied in primary human hepatocytes to assess the impact of rifampin.

Rifampin is commonly used to treat tuberculosis worldwide. It is well-known to induce the expression of many of the cytochrome P450 drug metabolism genes. It is also known to regulate the gene expression of several *ABC* drug transporters, but its effects on many of the transporters is yet unknown (Stapelbroek et al., [@B39]; Peters et al., [@B32]; Vilas-Boas et al., [@B42]; Weiss and Haefeli, [@B43]). Several clinically significant rifampin-induced drug-drug interactions have been documented (Niemi et al., [@B28]; Baciewicz et al., [@B1]). At least some of the rifampin effect is due to its binding to and activation of the pregnane X receptor (PXR). PXR is a transcription factor that regulates the expression of several of the *ABC* transporter genes (Mottino, [@B27]). In addition, rifampin can also regulate transporter expression indirectly by regulating microRNAs (miRNAs), which target the transporter mRNAs (Haenisch et al., [@B15]). miRNAs are short RNA sequences that regulate mRNA function by degrading the target mRNAs or blocking the mRNA translation. Rifampin induces hepatic expression of many miRNAs (Ramamoorthy et al., [@B34]), and miRNAs have been shown to regulate drug transporter expression and translation (Haenisch et al., [@B15]; Zhu et al., [@B48]; Bang and Thum, [@B3]), supporting the possibility that miRNAs mediate some of the effects of rifampin on transporter expression. In fact, this has been shown to be true where rifampin induces miRNA-379 expression in the HepG2 human liver cancer cell line and this miRNA subsequently down-regulates ABCC2 protein levels (Haenisch et al., [@B15]).

In this report, we addressed three aims. First, we determined the effect of rifampin on the expression of the 32 clinically relevant drug transporter genes in primary human hepatocytes. Next, we determined the association of the rifampin-mediated changes in transporter expression with the rifampin-mediated induction of miRNA expression. Lastly, we evaluated whether the effects of rifampin on several drug transporters in hepatocytes has any tissue specificity. Our results demonstrate the wide-reaching effects of rifampin on the expression of many transporter genes relevant to drug metabolism and disposition.

Methods {#s2}
=======

Human hepatocytes, drug treatment, RNA isolation, and miRNA profiling
---------------------------------------------------------------------

Our studies analyzed the RNA expression data collected by the studies done by Ramamoorthy et al. ([@B34]). In those studies, "human hepatocytes from seven different subjects were obtained from CellzDirect (Durham, NC)." The primary human hepatocytes were grown on collagen coated plates and treated with rifampin (10 μM) or vehicle (methanol, 0.01%) for 24 h. Each culture from a different individual subject was treated as a biologic replicate (*n* = 7). *In vitro* studies were performed within 72--120 h from the time of hepatocyte isolation. Total RNA and miRNA were isolated with a miRNeasy kit (Qiagen, Valencia, CA). miRNAs (754) were analyzed using the Taqman OpenArray Human miRNA Panel in technical duplicates (each sample run on two OpenArrays). Global mRNA expression was measured by RNA-seq conducted on the SOLiD4 system (Life Technologies, Inc, Carlsbad, CA). The hepatocyte tissues were purchased commercially, and were de-identified. These studies were not deemed human subject research. CellzDirect was purchased by another company, and specific demographic or clinical information on the donors was not transferred in the transition and the information could not be retrieved.

miRNA bioinformatics
--------------------

The miRNA bioinformatic analysis was re-performed from the original analysis done by Ramamoorthy et al. ([@B34]). For the technical duplicate values, the C~T~ values were averaged. If a miRNA had no value for both technical replicates, then it was assigned the highest C~T~ value of 40. In rare cases, if one technical duplicate detected the miRNA and the other technical duplicate was undetectable, the detectable value was used. To determine which miRNAs to include in the study, we selected only those with at least four of the seven control samples or four of the seven rifampin treated samples with average C~T~ values [\<]{.ul} 35. All the small nuclear RNA, U6 and RNUs, were removed. The remaining 333 miRNAs were Quantile normalized using PARTEK software. Quality control analysis after each normalization step included the visual evaluation of the histograms followed by principal component analysis (PCA) to identify systematic variations caused by various factors such as OpenArray runs. Normalized data were analyzed by ANOVA using a mixed effect model.

RNA sequencing analysis
-----------------------

Our studies used the data processing, quality assessment, sequence alignment, and gene expression analysis that was previously performed and published by Ramamoorthy et al. ([@B34]). As previously described for quality control, low quality. Briefly, RNA sequencing reads were removed including reads of less than 35 bases, or having a quality score of 20 or less. RNA was considered expressed if at least 10 reads were present after counts per million normalization.

Treatment and control groups were compared using the log~2~ transformed fold-change values. Of note, six data points in the transporter gene mRNA expression data were undetectable. Since a zero cannot be used in the log~2~ transformed fold-change calculations, the zero values were replaced with the minimum read numbers. The resultant *p*-values of the 410 transporters were corrected using a Benjamini and Hochberg\'s false discovery rate correction. A fold-change of one represents no change; a two-fold change is a doubling of the expression level.

Correlations of the rifampin effects on the expression of two transporter genes were performed using the Spearman rank correlations on the log~2~ transformed fold-change values. Correlations of the rifampin effect on specific gene expression with specific miRNA expression were also performed using the Spearman rank correlations on the log~2~ transformed fold-change using the delta C~T~ values for the miRNA expression.

Selection of transporters
-------------------------

All human transporter genes were identified using the University of California Santa Cruz reference genome using the following inputs: <http://genome.ucsc.edu/cgi-bin/hgTables>, criteria- group: genes and gene prediction, track: RefSeq Genes, table: RefGene, assembly: feb. 2009 (GRch37/hg19), clade: mammal, genome: human, region: genome, output format: selected fields from primary and related tables, click get output button, then on the next screen, check both- Name \[name of gen (usually transcript_id from GTF)\], and name 2 \[alternate name(e.g., gene_id from GTF)\] and then click get output. Selected transporters evaluated in our study were queried from this UCSC gene list. These human transporters were selected using a combination of literature, pharmADME.org, and NIH NCBI Gene using the term transporter, and using terms transporter, influx transporter, efflux transporter. Transporter gene families were chosen based on possible relevance to drug metabolism or clinical relevance.

Culture and rifampin treatment of renal cells
---------------------------------------------

Normal human proximal tubular kidney (NHPTK) cells were a gift from the Robert L. Bacallao Laboratory (Herbert et al., [@B18]). NHPTK cells are primary renal cells from a single donor immortalized with human telomerase plasmid transfection and maintained in REGM media (Lonza, Basel, Switzerland) supplemented with 10% fetal bovine serum (HyClone) to maintain their renal phenotype. NHPTK cells were diluted to 20--30% confluence three times a week and maintained at 37°C in 95% humidified atmosphere with 5% CO~2~. All *in vitro* studies were performed on cells in passages 6 through 9 (corresponds to passage 3 through 6 following immortalization). Cultures from each passage were treated as biologic replicates (*n* = 4). NHPTK cells were treated for 24 h with rifampin (10 μM) or with the vehicle control of methanol (0.01%).

Quantitative real-time PCR of renal cells
-----------------------------------------

Quantitative real-time polymerase chain reaction (qRT-PCR) was performed to measure the level of expression of *CYP3A4, GAPDH*, and other transporter genes in NHPTK cells. Since, the PXR expression was at the limit of detection in NHPTK cells, we measured PXR in HepG2 cells as a positive control to verify that are assay could detect the low quantity of PXR found in HepG2 cells. A total of 1 million cells were pelleted following rifampin or vehicle treatment, washed in ice-cold PBS, centrifuged to remove PBS, and stored at −80°C until RNA isolation. Total RNA was extracted using the miRNeasy Plus Mini Kit (Qiagen, Hilden, Germany) following the manufacturer\'s protocol. RNA quality assessment and quantification were conducted using the optical spectrometry 260/280 and 260/230 nm ratios. Subsequently, mRNA was reverse transcribed to cDNA using the Bio-Rad iScript Reverse Transcription Kit (Bio-Rad, Hercules, CA). The final concentration of cDNA was 25 ng/ml. qRT-PCR was performed with TaqMan Gene Expression Assays (Bio-Rad) for *CYP3A4*, using commercially obtained primers on the Bio-Rad iCycler RT-PCR system as previously described (Eadon et al., [@B8]). qRT-PCR for all other genes, including *GAPDH* as an endogenous control, was performed using custom made primers (Life Technologies) and iTaq Universal SYBR Green (Bio-Rad) on the Bio-Rad iCycler RT-PCR system. Primer sequences are provided in Supplemental Table [1](#SM1){ref-type="supplementary-material"}. Reactions were carried out in 20 μl volumes, which consisted of: 10 μl SYBR green, 4 μl cDNA, 0.4 μl of each primer (10 μM stock), and 5.2 μl of water. The RT-PCR reactions were run in triplicate. The thermocycler parameters were 95°C for 30 s, 40 cycles of 95°C for 15 s and then an annealing temperature for 30 s (provided in Supplemental Table [1](#SM1){ref-type="supplementary-material"}), with ramping speeds of 1.6--1.98 degrees °C/s and a melt curve. The C~T~ threshold and baseline for each experiment were set automatically by the Bio-Rad software. The delta-delta (ΔΔC~T~) method was used to obtain the relative expression of each gene for samples treated with rifampin or vehicle. Each sample\'s gene expression of interest was first subtracted from its *GAPDH* expression to determine its ΔC~T~. The ΔC~Tcontrol~ was then subtracted from the ΔC~Trifampin~ to determine the ΔΔC~T~. Fold-changes of the rifampin treatments as compared to the controls were determined by the formula: fold change = 2^ΔΔCT^. Gene expression for each condition is given as a fold-change ± SEM relative to the control where the SEM was calculated from individual ΔΔC~T~s of the 4 biologic replicates for each condition. Statistical significance was assessed based on a student\'s *t*-test between conditions.

*In silico* ChIP-Seq PXR binding site analysis
----------------------------------------------

A publically available chromosome immunoprecipitation DNA sequencing (ChIP-Seq) database available from Smith et al. ([@B38]) was analyzed *in silico* for PXR binding sites within the 410 transporter genes in this study (Smith et al., [@B38]). This ChIP-Seq dataset analyzed the PXR binding in rifampin treated vs. DMSO vehicle treated HepG2 cells.

Accession numbers
-----------------

The raw RNA-seq data have been made publically available through NCBI\'s Gene Expression Omnibus and are accessible through GEO Series accession number [GSE79933](GSE79933) (<http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE79933>). The miRNA OpenArray data have been made publically available at <http://compbio.iupui.edu/group/6/pages/rifampin>.

Results {#s3}
=======

Regulation of membrane transporters by rifampin
-----------------------------------------------

A total of 410 transporter genes from 19 transporter gene families were selected for analysis in the primary hepatocytes. Two hundred sixty-seven of the genes were in the *ABC* and *SLC* superfamilies of transporters. Thirty-four of the 267 are drug transporters that are considered to be clinically important for drug disposition (International Drug Transporter Consortium and/or PharmADME.org; International Transporter et al., [@B22]; Hillgren et al., [@B19]). Of the 32 transporters designated as "clinically relevant drug transporters" by the International Transporter Consortium (Table [1](#T1){ref-type="table"}), we expected at least 18 to be expressed in the hepatocytes (Hillgren et al., [@B19]). All 18 expected drug transporter genes were indeed found to be expressed in every donor sample; we also found six additional transporters that were previously not reported to be expressed in the liver (Table [2](#T2){ref-type="table"}). The expression of 12 of these drug transporter genes was modulated in the hepatocytes by rifampin (Table [2](#T2){ref-type="table"}). Rifampin induced the expression of 9 of the 12 drug transporter genes and the expression of three transporters was reduced. The results of the other 16 families of transporters (143 genes) we have characterized are provided in Supplemental Table [2](#SM2){ref-type="supplementary-material"}.

###### 

**Clinically important drug transporters**.

  **Influx**                                     **Gene name**   **Efflux**                                   **Gene name**   **Influx/Efflux**                                         **Gene name**
  ---------------------------------------------- --------------- -------------------------------------------- --------------- --------------------------------------------------------- ---------------
  [^\*^](#TN1){ref-type="table-fn"}**MCT1**      **SLC16A1**     [^\*^](#TN1){ref-type="table-fn"}**MDR1**    **ABCB1**       [^\*^](#TN1){ref-type="table-fn"}**ENT1**                 **SLC29A1**
  [^\*^](#TN1){ref-type="table-fn"}**PEPT1**     **SLC15A1**     [^\*^](#TN1){ref-type="table-fn"}**BCRP**    **ABCG2**       [^\*^](#TN1){ref-type="table-fn"}**ENT2**                 **SLC29A2**
  [^\*^](#TN1){ref-type="table-fn"}**OCT1**      **SLC22A1**     [^\*^](#TN1){ref-type="table-fn"}**MRP2**    **ABCC2**       [^\*^](#TN1){ref-type="table-fn"}**OSTalpha**             **SLC51A**
  [^\*^](#TN1){ref-type="table-fn"}**OAT2**      **SLC22A7**     [^\*^](#TN1){ref-type="table-fn"}**MRP3**    **ABCC3**       [^\*^](#TN1){ref-type="table-fn"}**OSTbeta**              **SLC51B**
  [^\*^](#TN1){ref-type="table-fn"}**OATP4C1**   **SLCO4C1**     [^\*^](#TN1){ref-type="table-fn"}**MATE1**   **SLC47A1**     [^\*^](#TN1){ref-type="table-fn"}**OCTN2**                **SLC22A5**
  [^\*^](#TN1){ref-type="table-fn"}**OATP2B1**   **SLCO2B1**     [^\*^](#TN1){ref-type="table-fn"}**MRP4**    **ABCC4**       \-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\--   
  [^\*^](#TN1){ref-type="table-fn"}**NTCP**      **SLC10A1**     [^\*^](#TN1){ref-type="table-fn"}**MRP6**    **ABCC6**       OAT4                                                      SLC22A11
  [^\*^](#TN1){ref-type="table-fn"}**OATP1B3**   **SLCO1B3**     [^\*^](#TN1){ref-type="table-fn"}**BSEP**    **ABCB11**      OCTN1                                                     SLC22A4
  [^\*^](#TN1){ref-type="table-fn"}**OATP1B1**   **SLCO1B1**     [^\*^](#TN1){ref-type="table-fn"}**MRP5**    **ABCC5**                                                                 
  [^\*^](#TN1){ref-type="table-fn"}**OAT7**      **SLC22A9**     \-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\--                                                                                      
  \-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\--              MATE2-K         SLC47A2                                                                                                                
  ASBT                                           SLC10A2                                                                                                                                
  PEPT2                                          SLC15A2                                                                                                                                
  URAT1                                          SLC22A12                                                                                                                               
  OAT3                                           SLC22A8                                                                                                                                
  OAT1                                           SLC22A6                                                                                                                                
  OCT2                                           SLC22A2                                                                                                                                
  OATP1A2                                        SLCO1A2                                                                                                                                

Clinical importance of drug transporters as determined by the International Transporter Consortium, and pharmADME.org.

*(**Bold**) The 24 genes with detectable expression in the primary human hepatocytes*.

###### 

**Rifampin-induced changes in gene expression of clinically relevant drug transporters**.

  **Common name**   **Gene name**   **Fold change**   ***p*-value**   **FDR**     **Example of substrates[^\*^](#TN2){ref-type="table-fn"}**
  ----------------- --------------- ----------------- --------------- ----------- --------------------------------------------------------------------------------------------------------------------------------------------------
  OSTbeta           *SLC51B*        12.67             1.20E-113       4.90E-111   Bile acids, conjugated steroids
  MRP2              *ABCC2*         1.85              3.56E-23        2.92E-21    Chemotherapy, statin, antepileptics, tamoxifen, DMARDs, antidepressants, clopidogrel, anti-retroviral
  MDR1              *ABCB1*         1.72              6.63E-18        3.02E-16    Chemotherapy, statin, antepileptics, tamoxifen, DMARDs, antidepressants, clopidogrel, anti-retroviral
  OATP2B1           *SLCO2B1*       1.73              2.34E-16        8.73E-15    Fexofenadine, montelukast, grapefruit, orange juice, apple juice, endogenous steroids
  MRP6              *ABCC6*         1.65              5.82E-14        1.84E-12    Thalidomide, docetaxel
  OATP1B3           *SLCO1B3*       −1.57             2.15E-11        5.18E-10    Irinotecan, docetaxe, myophenolate, statin, methotrexate
  OATP4C1           *SLCO4C1*       1.46              2.84E-07        3.88E-06    Estrone 3-sulfate
  MATE1             *SLC47A1*       1.37              2.64E-06        2.84E-05    Meformin, trimethoprim
  ENT1              *SLC29A1*       1.38              4.68E-06        4.80E-05    Gemcitabine, paclitaxe, gemcitabine, peginterferon, ribavirin
  OAT7              *SLC22A9*       −1.34             9.76E-05        0.0007      Methotrexate
  PEPT1             *SLC15A1*       −1.27             5.01E-04        0.0031      Statin, oseltamivir
  MRP3              *ABCC3*         1.18              0.0098          0.038       Cisplatin, MTX, doxorbuicn, cyclophosphamide, clopidogrel, codiene, morphine, etoposide
  OSTalpha          *SLC51A*        1.21              0.014           0.050       Bile acids, conjugated steroids
  BCRP              *ABCG2*         1.18              0.015           0.054       Antiepileptics, MTX, statin, anti-retrovirals, tecans, anti-neoplastics (irinotecan, platinum, anthracycline, taxane) acetaminophen, uric acid
  OCT1              *SLC22A1*       −1.16             0.019           0.060       Morphine, metformin, tramadol, antiemetics, dopamine agonist, antiretrovirals, sorafinib
  OAT2              *SLC22A7*       −1.15             0.040           0.11        Fluoropyrimidine, zidovudine
  MRP5              *ABCC5*         1.17              0.066           0.16        Antiepileptics, irinotecan
  MRP4              *ABCC4*         1.17              0.090           0.21        cisplatin, antiretroviral, bisphosphonates, MTX, acetaminophen, azathioprine, mercaptopurine
  NTCP              *SLC10A1*       −1.08             0.21            0.39        Bile acids
  OCTN2             *SLC22A5*       −1.08             0.30            0.51        Imatinib, oxaliplatin
  BSEP              *ABCB11*        −1.07             0.32            0.55        Statin
  OATP1B1           *SLCO1B1*       1.04              0.57            0.74        Simvastatin, statin, rifampin, irinotecan, methotrexate, thyroid, estrone sulfate, angiotensin receptor blocker, MTX, caspofungin, ace inhibitor
  MCT1              *SLC16A1*       1.03              0.61            0.78        Lactate
  ENT2              *SLC29A2*       −1.03             0.89            0.94        Gemcitabine, thiopurine

Primary human hepatocytes were treated with 10 μM Rifampin or vehicle for 24 h. Fold-change is the ratio of gene expression treatment/control. A fold-change equal 1 is defined as no change, and a fold change of 2 is defined as 2x the expression. FDR, False Discovery Rate.

*Cited from PharmGKB.org*.

Rifampin altered the expression of 62 of the 267 (\~23%) solute carrier (*SLC*) superfamily genes (Supplemental Table [2](#SM2){ref-type="supplementary-material"}). The fifteen *SLC* genes with the highest changes in expression levels are shown in Figures [1A,B](#F1){ref-type="fig"}. The expression of three out of the five (60%) detected genes of the *SLCO* family were also altered by rifampin (Supplemental Table [2](#SM2){ref-type="supplementary-material"}). PXR has been shown to regulate *SLCO2B1* and *SLCO1B1*, but the expression of only *SLCO2B1* increased (1.73-fold) in our study. In addition, rifampin altered the expression of 12 of the 38 (32%) ATP-binding cassette (*ABC*) superfamily transporter genes (Supplemental Table [3](#SM3){ref-type="supplementary-material"}). Eleven of these *ABC* genes were induced as shown in Figure [1C](#F1){ref-type="fig"}, and one (*ABCA8*) was reduced (Supplemental Table [2](#SM2){ref-type="supplementary-material"}).

![*****SLCs*** (including ***SLCOs***) and ***ABCs*** mRNA expressions regulated by rifampin with FDR \< 0.05. (A)** Induction of *SLCs* by rifampin by fold change (fold change represented as rifampin/control) (FDR \< 0.05); the top 15 *SLCs* are shown. **(B)** Reduction of *SLCs* by rifampin by fold change (fold change represented as control/rifampin) (FDR \< 0.05); the 15 most reduced *SLCs* are shown. **(C)** Rifampin induced 11 *ABC* transporter genes based on fold change (rifampin/control) with FDR \< 0.05. A fold change equal to 1 is defined as no change, and a fold change of 2 is defined as 2x the expression.](fphar-07-00111-g0001){#F1}

Correlations of the effect of rifampin on gene expression
---------------------------------------------------------

We next tested whether there were correlations in the effect of rifampin on the expression of drug transporter and cytochrome P450 (*CYP)* genes. Since each hepatocyte culture replicate was from a different donor, we considered each replicate a separate individual. There were nine pairs of drug transporters that were positively correlated (FDR \< 0.05; Figure [2](#F2){ref-type="fig"}; all CYP/Transporter gene expression correlations are found in Supplemental Table [3](#SM3){ref-type="supplementary-material"}), i.e., each pair of genes was upregulated (*r* [\>]{.ul} 0.79) upon rifampin treatment. We also correlated the rifampin effects on the drug transporters with rifampin effects on *CYP* gene expression. There were seven positive correlations (FDR \< 0.05; Figure [3](#F3){ref-type="fig"}; for the correlations of all CYP/Transporter genes see Supplemental Table [4](#SM4){ref-type="supplementary-material"}). Interestingly, four were correlations with *CYP4F2* (*SLCO2B1, SLC29A1, SLC47A1*, and *SLCO4C1*).

![**The significant correlations between the expression of clinically relevant transporter genes that were regulated by rifampin**. The expression \[represented by log~2~fold change (Log~2~FC)\] after rifampin treatment) was correlated for all 410 transporter genes. Only the significant correlation (*p* \< 0.05 by Spearman correlation) are shown for transporters regulated by rifampin with an FDR \< 0.05. Spearman correlation was performed because an assumption of normal distribution could not be made.](fphar-07-00111-g0002){#F2}

![**The significant correlations between the expression of drug metabolism genes and clinically relevant transporter genes that are regulated by rifampin**. The expression \[represented by log2fold change (Log2FC)\] after rifampin treatment was correlated between all CYP and 410 transporters genes. The figure illustrates, the seven significant positive and one significant negative correlations between the expression of CYP and drug transporter genes that were regulated by rifampin with an FDR \< 0.05. These were the only correlations with a *p* \< 0.05 by Spearman correlation. Spearman correlation was performed because an assumption of normal distribution could not be made.](fphar-07-00111-g0003){#F3}

Correlation between miRNA induction and changes of clinically relevant drug transporter expression
--------------------------------------------------------------------------------------------------

We have previously shown that rifampin induces the expression of several miRNAs in hepatocytes (Ramamoorthy et al., [@B34]). To identify drug transporters that may be modulated by these miRNAs, we determined the correlations between rifampin induction of miRNAs and the rifampin effect on drug transporter gene expression. The direct effects of the miRNAs on gene expression would be expected to downregulate transporter expression; however, since miRNAs could also have indirect effects and induce the expression of the drug transporter genes, we searched for both positive and negative correlations. We identified 14 highly correlated negative associations (Table [3](#T3){ref-type="table"}; for the correlations of the all transporter/miRNAs gene expression see Supplemental Table [5](#SM5){ref-type="supplementary-material"}). Three miRNAs, miR-320, miR-616, and miR-95, each correlated with two different drug transporters. Three drug transporters, *ABCB11, ABCC4, and ABCC5* were negatively correlated with two different miRNAs each. Based on the bioinformatics tools we employed, none of these were predicted to be direct effects. Only three rifampin-induced miRNAs were predicted to bind to drug transporters. Target Scan predicted miRNA binding of miR-335 to *SLC29A2*, miR-200b\# to *SLCO1B1*, and miR-616 to *SLCO1B1*. However, neither of these transporters genes expression were altered by rifampin.

###### 

**All clinically relevant drug transporters correlated with miRNA induced by rifampin with a ***p*** \< 0.05**.

  **miRNA**        **Gene**        **Spearman correlation**   ***p*-value**   **miRNA**       **Gene**        **Spearman correlation**   ***p*-value**
  ---------------- --------------- -------------------------- --------------- --------------- --------------- -------------------------- ---------------
  hsa-miR-200b\#   *SLCO1B1*       0.96                       0.0028          hsa-miR-107     *SLC16A1*       −0.96                      0.0028
  hsa-miR-766      *ABCG2*         0.96                       0.0028          hsa-miR-202     ***SLC22A9***   −0.93                      0.0067
  hsa-miR-660      *ABCB11*        0.96                       0.0028          hsa-miR-616     *SLC22A5*       −0.93                      0.0067
  hsa-miR-660      *ABCC6*         0.93                       0.0067          hsa-miR-95      *ABCB11*        −0.93                      0.0067
  hsa-miR-616      *ABCC5*         0.89                       0.012           hsa-miR-335     *ABCC4*         −0.93                      0.0067
  hsa-miR-886-3p   ***SLC51B***    0.89                       0.012           hsa-miR-320     *ABCC5*         −0.89                      0.012
  hsa-miR-886-3p   *SLC51A*        0.89                       0.012           hsa-miR-638     *ABCC5*         −0.86                      0.024
  hsa-miR-766      *SLCO1B1*       0.86                       0.024           hsa-miR-186     *SLC29A2*       −0.86                      0.024
  hsa-miR-660      ***SLC47A1***   0.86                       0.024           hsa-miR-92a     *ABCC4*         −0.83                      0.021
  hsa-miR-335      *SLC29A2*       0.86                       0.024           hsa-miR-320     *ABCB11*        −0.82                      0.034
  hsa-miR-107      *SLC22A7*       0.82                       0.034           hsa-miR-616     *SLCO1B1*       −0.79                      0.048
  hsa-miR-660      ***SLCO2B1***   0.82                       0.034           hsa-miR-30d\#   ***SLC29A1***   −0.79                      0.048
  hsa-miR-660      ***SLCO4C1***   0.82                       0.034           hsa-miR-95      ***SLC47A1***   −0.79                      0.048
  hsa-let-7g       *SLC51A*        0.82                       0.034           hsa-miR-92a     ***SLCO1B3***   −0.76                      0.049
  hsa-miR-766      *SLCO2B1*       0.79                       0.048                                                                      
  hsa-miR-660      ***ABCC2***     0.79                       0.048                                                                      
  hsa-miR-660      *SLC22A1*       0.79                       0.048                                                                      

*Correlation was assessed for all miRNA tested and the 410 transporters expressed in hepatocytes. Shown in this table are the all the clinically relevant drug transporters regardless of rifampin regulation with the miRNAs induced by rifampin with a p \< 0.05. In bold, the subset of the only clinically relevant transporters whose expression was regulated by rifampin with an FDR \< 0.05 and correlated with rifampin induced miRNAs. Spearman correlation selected as samples because assumption of normal distribution could not be made*.

We identified 18 highly positive correlations between the rifampin effects on miRNAs and its effects on drug transporter expression levels (Table [3](#T3){ref-type="table"}; Supplemental Table [5](#SM5){ref-type="supplementary-material"}). miR-660 positively correlated with seven different transporters, miR-766 positively correlated with three transporters, and miR-886-3p and let-7g positively correlated with two transporters. None of the rifampin-induced miRNAs were predicted to bind to any of the rifampin-regulated drug transporters.

Rifampin\'s modulation of drug transporter gene expression is tissue specific
-----------------------------------------------------------------------------

Many of the drug transporters that we detected in the hepatocytes are also expressed in other tissues, including the kidney (Hillgren et al., [@B19]). Thus, we determined if rifampin demonstrated any tissue specificity by regulating the same transporters in human kidney cells. Normal human proximal tubular kidney (NHPTK) cells were treated with rifampin analogously to primary hepatocytes, and gene expression was measured. Seven transporters were selected based on their differential expression in hepatocytes and their renal proximal tubular relevance. Expression of *SLC22A1, SLC22A5, SLC15A1, SLC29A1, SLCO4C1, MRP2, and MRP4* was detected, but did not change significantly following rifampin treatment (Supplemental Figure [1A](#SM8){ref-type="supplementary-material"}; statistics are provided in Supplemental Table [6](#SM6){ref-type="supplementary-material"}). *CYP3A4* expression was low in NHPTK cells with raw C~T~ values between 35 and 37. Expression was not significantly elevated following rifampin treatment (Supplemental Figure [1B](#SM8){ref-type="supplementary-material"}). As CYP3A4 is PXR dependent, gene expression of *NR1I2 (PXR)* was also measured in NHPTK cells and compared to *NR1I2* expression in a positive control cell line, HepG2 cells. Since we expected *NR1I2* expression to be much lower than hepatocytes, we used HepG2 as a positive control, which is known to have relatively low *NR1I2* expression levels (Gerets et al., [@B12]). The expression of *NR1I2* was much lower in NHPTK cells when compared to HepG2 (Supplemental Figure [1C](#SM8){ref-type="supplementary-material"}).

38 Transporters have rifampin induced PXR binding sites
-------------------------------------------------------

Utilizing a publically available ChIP-Seq database from Smith et al. ([@B38]), Figure [4](#F4){ref-type="fig"} illustrates our *in silico* analysis of this dataset. The 410 transporter genes were mapped to Ensembl annotation. The transcription start site (TSS) was located for each gene and a promoter region was defined as ± 2 kilobases from TSS of each gene. From the ChIP-Seq dataset, 6302 PXR peaks were identified in the rifampin treated HepG2 cells and 1157 PXR peaks in DMSO treated HepG2. PXR peaks were extracted only if uniquely found in rifampin treated HepG2 vs. DMSO vehicle. The remaining 6063 unique rifampin peaks were compared for overlap with the 410 promoter regions of the transporters. 58 of the 410 transporter genes\' promoter regions were identified to have PXR binding sites. Table [4](#T4){ref-type="table"} illustrates the PXR binding site for one isoform of each gene transcript, while Supplemental Table [7](#SM7){ref-type="supplementary-material"} provides a list of the PXR binding site analysis for all gene transcript isoforms. Thirty three members of the *SLC* (*SLC10A7, SLC16A3, SLC17A5, SLC1A4, SLC20A1, SLC20A2, SLC22A15, SLC22A3, SLC23A2, SLC25A1, SLC25A10, SLC25A11, SLC25A22, SLC25A4, SLC25A42, SLC25A5, SLC26A2, SLC29A1, SLC2A1, SLC2A10, SLC30A10, SLC37A3, SLC39A7, SLC39A8, SLC3A2, SLC41A2, SLC43A1, SLC47A1, SLC5A11, SLC5A3, SLC5A9, SLC7A5*, and *SLCO2B1*), and 7 members of the *ABC* (*ABCA2, ABCA3, ABCA9, ABCB4, ABCC10, ABCC2*, and *ABCC3*) superfamily of transporters have PXR binding sites. Five of the clinically relevant drug transporter genes, *ABCC2, ABCC3, SLC29A1, SLC47A1*, and *SLCO2B1* were found to have PXR peaks within their promoter regions.

![**Illustration of the ***in silico*** ChIP-Seq testing for PXR binding sites within the 410 transporters**. Rif, rifampin; TSS, Transcription Start Site.](fphar-07-00111-g0004){#F4}

###### 

**The 58 transporters with ChIP-Seq determined PXR binding sites**.

  **Gene**     **Transcript ID (Isoform)**   **Chromosome**   **Start of transcription start site (TSS)**   **Strand**   **Distance from the center of the PXR binding peak to the TSS**
  ------------ ----------------------------- ---------------- --------------------------------------------- ------------ -----------------------------------------------------------------
  *SLC2A1*     ENST00000415851               chr1             43424501                                      −            228.5
  *SLC5A9*     ENST00000425816               chr1             48688357                                      \+           −1875.5
  *ABCD3*      ENST00000394233               chr1             94883933                                      \+           −233
  *SLC22A15*   ENST00000369503               chr1             116519119                                     \+           884.5
  *ANXA9*      ENST00000368947               chr1             150954493                                     \+           97.5
  *ATP1B1*     ENST00000367816               chr1             169074935                                     \+           22.5
  *SLC30A10*   ENST00000366926               chr1             220101945                                     −            2161.5
  *ANXA11*     ENST00000481805               chr10            81928844                                      −            −190.5
  *ABCC2*      ENST00000370449               chr10            101542489                                     \+           −195
  *SLC25A22*   ENST00000524891               chr11            795007                                        −            −46.5
  *PEX16*      ENST00000527371               chr11            45937095                                      −            −2271.5
  *SLC43A1*    ENST00000533515               chr11            57267151                                      −            2075
  *SLC3A2*     ENST00000544377               chr11            62647894                                      \+           470.5
  *SLCO2B1*    ENST00000526839               chr11            74876919                                      \+           −884
  *CACNA2D4*   ENST00000588896               chr12            1905116                                       −            −248.5
  *SCN8A*      ENST00000546961               chr12            51984050                                      \+           424
  *ATP2B1*     ENST00000428670               chr12            90102609                                      −            −682.5
  *SLC41A2*    ENST00000432951               chr12            105352067                                     −            −234.5
  *SCARB1*     ENST00000541205               chr12            125324218                                     −            1402
  *ATP11A*     ENST00000487903               chr13            113344643                                     \+           −604.5
  *ABCA3*      ENST00000563623               chr16            2390599                                       −            −384.5
  *SLC5A11*    ENST00000347898               chr16            24857162                                      \+           −1215.5
  *SLC7A5*     ENST00000563489               chr16            87870412                                      −            −1384.5
  *SLC25A11*   ENST00000570543               chr17            4841853                                       −            −1323.5
  *SLC47A1*    ENST00000571335               chr17            19436775                                      \+           −62
  *ABCC3*      ENST00000503304               chr17            48745791                                      \+           −353.5
  *ABCA9*      ENST00000461623               chr17            67045499                                      −            1577.5
  *KCNJ2*      ENST00000535240               chr17            68164814                                      \+           1032
  *ATP5H*      ENST00000538432               chr17            73043046                                      −            190
  *MFSD11*     ENST00000590070               chr17            74769179                                      \+           2135
  *SLC25A10*   ENST00000541223               chr17            79670404                                      \+           87.5
  *SLC16A3*    ENST00000582743               chr17            80186908                                      \+           2067.5
  *ATP9B*      ENST00000590608               chr18            76886267                                      \+           −1304
  *SLC25A42*   ENST00000318596               chr19            19174808                                      \+           −476
  *SLC1A4*     ENST00000493121               chr2             65215611                                      \+           1472
  *SLC20A1*    ENST00000272542               chr2             113403434                                     \+           −488
  *ATP5G3*     ENST00000392541               chr2             176046392                                     −            −105.5
  *SLC23A2*    ENST00000423430               chr20            4880294                                       −            887.5
  *SLC2A10*    ENST00000359271               chr20            45338126                                      \+           124.5
  *SLC5A3*     ENST00000381151               chr21            35445870                                      \+           34.5
  *PEX26*      ENST00000329627               chr22            18560689                                      \+           −1844.5
  *SLC25A1*    ENST00000461267               chr22            19165994                                      −            −31.5
  *SCARB2*     ENST00000511129               chr4             77088018                                      −            949
  *SLC39A8*    ENST00000394833               chr4             103266297                                     −            412
  *SLC10A7*    ENST00000507030               chr4             147442870                                     −            −390
  *SLC25A4*    ENST00000281456               chr4             186064395                                     \+           15
  *SLC26A2*    ENST00000286298               chr5             149340300                                     \+           −390
  *ANXA6*      ENST00000522664               chr5             150484834                                     −            319.5
  *SLC39A7*    ENST00000444757               chr6             33168222                                      \+           −418.5
  *ABCC10*     ENST00000372515               chr6             43395104                                      \+           618.5
  *SLC29A1*    ENST00000393844               chr6             44187242                                      \+           1915
  *SLC17A5*    ENST00000393019               chr6             74363697                                      −            93.5
  *SLC22A3*    ENST00000275300               chr6             160769300                                     \+           1939.5
  *ABCB4*      ENST00000453593               chr7             87104782                                      −            −315.5
  *SLC37A3*    ENST00000340308               chr7             140098258                                     −            −58
  *SLC20A2*    ENST00000518717               chr8             42396198                                      −            194.5
  *ABCA2*      ENST00000492260               chr9             139922624                                     −            1220.5
  *SLC25A5*    ENST00000317881               chrX             118602363                                     \+           714.5

*In silico analysis utilizing a publically available HepG2 ChIP-Seq database to test the 410 transporter genes for PXR binding after rifampin treatment. Of the 410 transporter genes analyzed, 58 transporters were found to have PXR binding sites*.

Discussion {#s4}
==========

Our study has several important first-time characterizations of rifampin\'s direct and indirect regulation of membrane transporters. First, rifampin regulates the gene expression of many members of the two major superfamilies (*ABC and SLC*) involved with clinically relevant drug transport. Second, the modulation of rifampin of transporter gene expression is associated with changes in miRNA expression. Third, we demonstrated that the effect of rifampin on transporter gene expression is tissue-specific. To the best of our knowledge, this study provides the first global characterization of rifampin induction of drug transporter gene expression.

Our studies demonstrate that rifampin treatment induces the gene expression of many members of the *SLCO, SLC*, and *ABC* transporter families. Twelve *ABC* transporter genes were regulated either directly or indirectly by rifampin; of these 12 *ABC* transporters genes, five of have previously been shown to be regulated by rifampin (Nishimura et al., [@B29]; Teng et al., [@B40]; Stapelbroek et al., [@B39]; Vilas-Boas et al., [@B42]; Weiss and Haefeli, [@B43]; Williamson et al., [@B45]) and two of the three *ABC* genes with the smallest *p*-values in our data set were drug transporters (*ABCC2, and ABCB1*). *ABCC2* and *ABCB1* have been shown to be induced by the nuclear receptor, PXR (Geick et al., [@B11]; Kast et al., [@B23]). Our analysis of a publically available ChIP-Seq dataset confirmed that *ABCC2* has a PXR binding site within the promoter region. *ABCB1* was not found to have a PXR binding site by our in silico ChIP-Seq analysis. PXR mediates at least part of the rifampin effects through direct binding to rifampin and nuclear localization (Stapelbroek et al., [@B39]; Honorat et al., [@B20]; Roques et al., [@B35]; Vilas-Boas et al., [@B42]; Weiss and Haefeli, [@B43]; Williamson et al., [@B45]). We likely did not identify the *ABCB1* PXR binding site within the promoter region due to defining the promoter region using the common convention of ± 2 kilobases around the TSS. In Kast et al. ([@B23]), the *ABCB1* PXR binding site was over 7 kilobases from the TSS.

In the *SLC* family, the expression of 44 transporters were induced by rifampin. The most highly induced *SLC* transporter gene was the clinically relevant drug transporter *SLC51B* (*OSTbeta*; \>12-fold), which is a newly recognized transporter that heterodimerizes with OST alpha and transports bile acids and conjugated steroids (Ballatori et al., [@B2]). For comparison, CYP3A4 was induced 22-fold (Ramamoorthy et al., [@B34]). We used a similar method of analyzing the data as Ramamoorthy et al., and with the same RNA-seq data set, CYP3A4 was induced 22-fold in our analysis as well. None of the *SLC* drug transporter genes (excluding *SLCOs*) have previously been shown to be induced by PXR or rifampin (Dixit et al., [@B7]). Our ChIP-Seq analysis identified that 33 *SLC* genes (Table [4](#T4){ref-type="table"} and Supplemental Table [7](#SM7){ref-type="supplementary-material"}) had PXR binding sites. The two clinically relevant drug transporter *SLC* genes with a PXR binding peak identified in their promoter region were *SLC29A1*, and *SLC47A1*. The genes were induced by rifampin 1.38- and 1.37-fold (*p* \< 0.05) respectively. *SLC51B* was not one of them. Although PXR and rifampin regulation of *SLC* transporters was mentioned in a review article (Ihunnah et al., [@B21]), we have been unable to find any published data supporting their statement for rifampin or PXR, but our ChIP-Seq analysis suggests that the rifampin induction of much of the *SLC* gene expression may be through other transcription factors (Rae et al., [@B33]; Hagenbuch and Meier, [@B17]).

In the *SLCO* family, two transporter genes (*SLCO4C1 and SLCO2B1*) were induced by rifampin; both are clinically relevant drug transporter genes. Neither of these *SLCO*s expressions have been previously shown to be altered by rifampin or PXR. Based on our ChIP-Seq data, *SLCO2B1* has a PXR binding site in their promoter.

Overall, five of the 12 rifampin induced clinically relevant transporters have PXR binding sites by ChIP-Seq analysis. With an additional sixth gene, *ABCB1*, having a published report of a PXR binding site, half of the rifampin induction of the clinical relevant transporter gene expression in this study was likely in part due to PXR activation. Our data suggest that a smaller portion of the induction of all *ABCs, SLCs, and SLCOs* gene expressions by rifampin is through PXR.

Furthermore, rifampin also reduced the gene expression of three clinically relevant drug transporters (*SLC15A1, SLC22A9, and SLCO1B3*). Of these transporter, only SLCO1B3 expression has studies evaluating rifampin regulation of gene expression. SLCO1B3 gene expression was shown not to change in primary hepatocytes when subjected to similar conditions (24 h 10 μM rifampin treatment; Williamson et al., [@B45]). Hafner et al. ([@B16]) showed no change in SLCO1B3 after 48 h of rifampicin treatment. After 72 h of rifampin, SLCO1B3 is only moderately elevated (Dixit et al., [@B7]). These studies and ours suggest that the length of exposure to rifampin likely changes the level of SLCO1B3 gene expression. Additionally, Williamson et al. ([@B45]) also showed an inhibition of SLCO1B3 expression as the rifampin concentration increased from 0.5 to 10 μM. A possible mechanism of this initial inhibition may be an indirect induction of repressors that reduce drug transport gene expression through PXR (Zhou et al., [@B47]; Tojima et al., [@B41]; Sehirli et al., [@B36]; Zhang et al., [@B46]). Also, we must consider that rifampin is activating other transcription factors. Another possibility may be inhibition of drug transport gene expression through induction, possibly through PXR of miRNAs (Ramamoorthy et al., [@B34]).

MicroRNAs are potentially involved in the effect rifampin exerts on the expression of clinically relevant drug transporter genes. For example, four transporters genes were negatively correlated with rifampin-induced miRNA expression: *SLC47A1/*miR-95*, SLC29A1/*miR-30d\#, *SLC22A9/*miR-202*, and SLCO1B3/*miR-92a (Table [3](#T3){ref-type="table"}). Only *SLCO1B3* and *SLC22A9* gene expression were reduced after rifampin treatment. This was surprising because no seed binding sites were predicted for the rifampin-induced miRNAs in the 3′ UTRs of these transporter genes (data not shown). Possibly, gene reduction may occur through less well understood miRNA binding in other mRNA regions (e.g., coding and 5′ UTR regions; Clark et al., [@B5]).

Rifampin\'s ability to alter gene expression patterns also demonstrated tissue specificity. Since the kidney proximal tubules express transporters that may contribute to plasma drug concentrations, we chose to study a proximal kidney cell line to explore the effects of rifampin on clinically relevant drug transporter gene expression. We used human proximal tubular epithelial cells, NHPTK, because of the known role of the proximal tubules in organic cation, anion, and drug transport (Giacomini et al., [@B14]; Kido et al., [@B25]). This cell line closely resembles primary proximal tubular cells with a renal phenotype that includes, parathyroid hormone responsiveness, tight junction formation, and transporter expression and function (Wieser et al., [@B44]; Herbert et al., [@B18]). High levels of drug transporter mRNA expression was detected, but rifampin did not induce or reduce transporter expression in a significant manner. This finding is in agreement with prior studies evaluating rifampin effects on individual renal drug transporters expression. For example, rifampin did not lead to alterations in *SLC22A2* expression in MDCK cells (Shu et al., [@B37]). Renal gene expression of *NR1I2* (*PXR)* is minimal in contrast to levels observed in liver and intestine (Cheng and Klaassen, [@B4]). Although renal transporter expression did not increase with rifampin treatment, this is likely secondary to low intracellular PXR protein concentrations. PXR appears to be a major determinant for rifampin\'s tissue selective regulation of drug transporters.

Our study has several strengths. First, primary human hepatocytes serve as an *in-vitro* system to predict changes in gene expression patterns in the human liver. Second, RNA sequencing allowed us to characterize all of the clinically relevant drug transporter genes that are expressed in human liver. Third, this approach allowed us to determine relationships between the gene expression patterns of the clinically relevant drug transporters, drug metabolizing enzymes, and miRNAs. Lastly, our findings provide a blue print for future investigations exploring rifampin\'s regulation of the transporter function.

There are a few secondary issues of some importance worth addressing. This study also produced a wealth of data on transporters that are not yet known to be clinically relevant for drug transport. In fact, the vast majority of *ABC* and *SLC* family members have not yet been shown to be clinically relevant to drug transport. The *SLC* superfamily is of particular interest in drug therapeutics as it includes transporters for e.g., serotonin, norepinephrine, and glucose that are drug targets (Gether et al., [@B13]; David-Silva et al., [@B6]; Felts et al., [@B9]). *SLC5A12* for instance is a sodium-coupled monocarboxylate transporter (SMCT-2) that regulates the lactic acid levels in the blood and has been linked to nicotine uptake (Ohkubo et al., [@B30]; Garnett et al., [@B10]); this gene was found in our study to be highly induced (\>7-fold increase) by rifampin. Hence, our systematic characterization of transporter gene expression provides a more complete picture of the effects of rifampin on transporters at large. This information can inform the selection of gene targets for future mechanistic studies of transporter function.

Our study also has some limitations. Hepatocytes from only 7 different individuals is not sufficient to determine the population variability of the effects of rifampin. Using hepatocytes from seven donors for this study should identify the major transporters that are commonly regulated by rifampin (Kato et al., [@B24]); however, there may be some transporters that were not statistically significantly regulated by rifampin due to the low sample number, but are in fact regulated in some subpopulations of individuals. Another limitation is that the impact of genetic variation on expression levels was not taken into account. We also acknowledge that the fold-changes for the clinically relevant drug transporter gene expression were 1.18 to 1.85-fold. However, the levels of transporter mRNA expression have been highly correlated with their protein expression (when protein levels were analyzed by mass spectrometry; Ohtsuki et al., [@B31]; Lee et al., [@B26]). Also, these changes in expression levels represent a single time point, i.e., 24 h after rifampin treatment. Many of the correlations may not be direct, and represent inhibition of repressors or induction of co-activators. We also note that the ChIP-Seq dataset from HepG2 cells may not represent all of the PXR induction seen in primary hepatocytes, and limiting the promoter region to ± 2 kilobases around the TSS may have limited the detection of all PXR binding sites.

In conclusion we identified clinically relevant drug transporters exhibiting measurable changes that occur within a relatively short time period after treatment with rifampin. The coordinated changes of transporter expression by rifampin, and other potential inducing/repressing factors, may contribute to transporter-mediated drug-drug interactions. The rifampin-regulated transporters that we identified would be candidates for further investigations to understand the mechanisms (e.g., direct promoter regulation by PXR, indirect effects through miRNAs) involved in the up- and down-regulation of these transporters. Rifampin may serve as a representative ligand of many other PXR ligands (e.g., carbamazepine, St. John\'s Wort) may also cause effects on transporter expression similar to that of rifampin.
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